close
References
  1. North American Menopause Society. Menopause 101: a primer for the perimenopausal. www.menopause.org/for-women/menopauseflashes/menopause-symptoms-and-treatments/menopause-101-a-primer-for-the-perimenopausal. Accessed October 22, 2020.
  2. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 141: management of menopausal symptoms. Obstet Gynecol. 2014;123(1):202-216.
  3. Kronenberg F. Hot flashes: epidemiology and physiology. Ann N Y Acad Sci. 1990;592:52-86.
  4. North American Menopause Society. The North American Menopause Society statement on continuing use of systemic hormone therapy after age 65. Menopause. 2015;22(7):693.
  5. Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531-539.
  6. Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause. 2014;21(9):924-932.
  7. Whiteley J, Wagner JS, Bushmakin A, Kopenhafer L, DiBonaventura M, Racketa J. Impact of the severity of vasomotor symptoms on health status, resource use, and productivity. Menopause. 2013;20(5):518-524.
  8. Anderson GO, Gelfeld V. Menopause experiences: providers can do better in educating, starting the conversation. July 2018. AARP. www.aarp.org/research/topics/health/info-2018/menopause-experiences-healthcare. Accessed October 22, 2020.
  9. Wolff J. What doctors don’t know about menopause. AARP The Magazine. August/September 2018. www.aarp.org/health/conditions-treatments/info-2018/menopause-symptoms-doctors-relief-treatment.html. Accessed October 22, 2020.
  10. Kraft S. Why so many doctors fail women with menopause care. Next Avenue. October 10, 2019. www.nextavenue.org/doctors-fail-women-menopause-care/. Accessed October 22, 2020.
  11. Heubeck E. Menopause’s long learning curve. Hartford Courant. July 12, 2019. www.courant.com/health/hc-ls-chit-menopause-20190714-20190712-rkdoivfuefhydhkkndcggl7mpu-story.html. Accessed October 22, 2020.
  12. Goldstein S. An efficient tool for the primary care management of menopause. Can Fam Physician. 2017;63(4):295-298.
  13. Sarrel PM. A call to increase the use of hormone therapy to prevent disease in symptomatic postmenopausal women. Menopause. 2019;26(6):1-3.
  14. Pinkerton JV. Hormone therapy for postmenopausal women. N Engl J Med. 2020;382(5):446-455.
  15. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011.
  16. North American Menopause Society. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728-753.
  17. Jane FM, Davis SR. A practitioner's toolkit for managing the menopause. Climacteric. 2014;17(5):564-579.
  18. Duavee prescribing information. Wyeth Pharmaceuticals; 2020.
  19. Umland EM, Karel L, Santoro N. Bazedoxifene and conjugated equine estrogen: a combination product for the management of vasomotor symptoms and osteoporosis prevention associated with menopause. Pharmacotherapy. 2016;36(5):548-561.
  20. Biglia N, Bounous VE, De Seta F, Lello S, Nappi RE, Paoletti AM. Non-hormonal strategies for managing menopausal symptoms in cancer survivors: an update. Ecancermedicalscience. 2019;13:909.
  21. Leon-Ferre RA, Novotny PJ, Wolfe EG, et al. Oxybutynin vs placebo for hot flashes in women with or without breast cancer: a randomized, double-blind clinical trial (ACCRU SC-1603). JNCI Cancer Spectr. 2020;4(1):pkz088.
  22. Pinkerton JV, Santen RJ. Managing vasomotor symptoms in women after cancer. Climacteric. 2019;22(6):544-552.
  23. Guttuso T Jr. Stellate ganglion block for treating hot flashes: a viable treatment option or sham procedure? Maturitas. 2013;76(3):221-224.
  24. Walega DR, Rubin LH, Banuvar S, Shulman LP, Maki PM. Effects of stellate ganglion block on vasomotor symptoms: findings from a randomized controlled clinical trial in postmenopausal women. Menopause. 2014;21(8):807-814.
  25. Gerard C, Mestdagt M, Tskitishvili E, et al. Combined estrogenic and anti-estrogenic properties of estetrol on breast cancer may provide a safe therapeutic window for the treatment of menopausal symptoms. Oncotarget. 2015;6(19):17621-17636.
  26. Reame NK. Estetrol for menopause symptoms: the Cinderella of estrogens or just another fairy tale? Menopause. 2020;27(8):841-843.
  27. Depypere H, Timmerman D, Donders G, et al. Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial. J Clin Endocrinol Metab. 2019;104(12):5893-5905.
  28. Fraser GL, Lederman S, Waldbaum A, et al. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. Menopause. 2020;27(4):382-392.
  29. Astellas. Astellas initiates phase 3 clinical trials for fezolinetant in postmenopausal women with vasomotor symptoms. August 6, 2019.
  30. Johnson A, Roberts L, Elkins G. Complementary and alternative medicine for menopause. J Evid Based Integr Med. 2019;24:2515690X19829380.
  31. Kandiah J, Amend V. An exploratory study on perceived relationship of alcohol, caffeine, and physical activity on hot flashes in menopausal women. Health. 2010;2(9):989-996.
  32. Faubion SS, Sood R, Thielen JM, Shuster LT. Caffeine and menopausal symptoms: what is the association? Menopause. 2015;22(2):155-158.
  33. Kim KH, Kang KW, Kim DI, et al. Effects of acupuncture on hot flashes in perimenopausal and postmenopausal women—a multicenter randomized clinical trial. Menopause. 2010;17(2):269-280.
  34. Leach MJ, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms. Cochrane Database Syst Rev. 2012;2012(9):CD007244.